Forte Biosciences (FBRX) Return on Capital Employed (2017 - 2026)
Forte Biosciences (FBRX) posted quarterly Return on Capital Employed of 149.89% for Q1 2026, down 5111.0% year-over-year from 2.99% in Q1 2025, and down 46.76% quarter-over-quarter from 102.13% in Q4 2025.
Forte Biosciences (FBRX) Return on Capital Employed (2017 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Return on Capital Employed for 10 consecutive years, with 149.89% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 5111.0% year-over-year to 149.89%; the TTM figure through Mar 2026 stood at 149.89% (down 5111.0% YoY), while the FY2025 annual figure was 137.41%, down 4855.0% from the prior year.
- Return on Capital Employed declined to 149.89% in Q1 2026 per FBRX's latest filing, from 102.13% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 30.54% in Q3 2022 and bottomed at 265.28% in Q3 2024.
- Historically, Return on Capital Employed has averaged 95.38% across 5 years, with a median of 87.72% in 2023.
- Annual changes were most pronounced in 2024 — Return on Capital Employed slumped 16845 bps — and 2025, when it surged 20553 bps.
- Forte Biosciences' Return on Capital Employed stood at 34.41% in 2022, then sank by 137 bps to 81.7% in 2023, then sank by 46 bps to 119.33% in 2024, then gained by 14 bps to 102.13% in 2025, then slumped by 47 bps to 149.89% in 2026.
- Business Quant data shows FBRX's Return on Capital Employed at 149.89% in Q1 2026, 102.13% in Q4 2025, and 59.74% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | -77.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -77.45% |
| Mar 31, 2026 | -149.89% |
| Dec 31, 2025 | -102.13% |
| Sep 30, 2025 | -59.74% |
| Jun 30, 2025 | -63.82% |
| Mar 31, 2025 | -98.78% |
| Dec 31, 2024 | -119.33% |
| Sep 30, 2024 | -265.28% |
| Jun 30, 2024 | -186.74% |
| Mar 31, 2024 | -103.94% |
| Dec 31, 2023 | -81.70% |
| Sep 30, 2023 | -96.83% |
| Jun 30, 2023 | -87.72% |
| Mar 31, 2023 | -51.24% |
| Dec 31, 2022 | -34.41% |
| Sep 30, 2022 | -30.54% |
| Jun 30, 2022 | -42.39% |
| Mar 31, 2022 | -46.92% |
| Dec 31, 2021 | -49.29% |
| Sep 30, 2021 | -48.88% |